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Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK
Across the Entire Care Pathway in a SingleWhole-DiseaseModel
Huajie Jin, PhD; Paul Tappenden, PhD; James H. MacCabe, PhD; Stewart Robinson, PhD; Sarah Byford, PhD
Abstract
IMPORTANCE The existing economic models for schizophrenia often have 3 limitations; namely,
they do not cover nonpharmacologic interventions, they report inconsistent conclusions for
antipsychotics, and they have poor methodologic quality.
OBJECTIVES To develop a whole-disease model for schizophrenia and use it to inform resource
allocation decisions across the entire care pathway for schizophrenia in the UK.
DESIGN, SETTING, ANDPARTICIPANTS This decision analytical model used awhole-diseasemodel
to simulate the entire disease and treatment pathway among a simulated cohort of 200000
individuals at clinical high risk of psychoses or with a diagnosis of psychosis or schizophrenia being
treated in primary, secondary, and tertiary care in the UK. Data were collected March 2016 to
December 2018 and analyzed December 2018 to April 2019.
EXPOSURES The whole-disease model used discrete event simulation; its structure and input data
were informed by published literature and expert opinion. Analyses were conducted from the
perspective of the National Health Service and Personal Social Services over a lifetime horizon. Key
interventions assessed included cognitive behavioral therapy, antipsychotic medication, family
intervention, inpatient care, and crisis resolution and home treatment team.
MAINOUTCOMESANDMEASURES Life-time costs and quality-adjusted life-years.
RESULTS In the simulated cohort of 200000 individuals (mean [SD] age, 23.5 [5.1] years; 120 800
[60.4%]men), 66 400 (33.2%) were not at risk of psychosis, 69 800 (34.9%) were at clinical high
risk of psychosis, and 63 800 (31.9%) had psychosis. The results of the whole-diseasemodel suggest
the following interventions are likely to be cost-effective at a willingness-to-pay threshold of
£20000 ($25 552) per quality-adjusted life-year: practice as usual plus cognitive behavioral therapy
for individuals at clinical high risk of psychosis (probability vs practice as usual alone, 0.96); amix of
hospital admission and crisis resolution and home treatment team for individuals with acute
psychosis (probability vs hospital admission alone, 0.99); amisulpride (probability vs all other
antipsychotics, 0.39), risperidone (probability vs all other antipsychotics, 0.30), or olanzapine
(probability vs all other antipsychotics, 0.17) combined with family intervention for individuals with
first-episode psychosis (probability vs family intervention or medication alone, 0.58); and clozapine
for individuals with treatment-resistant schizophrenia (probability vs other medications, 0.81).
CONCLUSIONS ANDRELEVANCE The results of this study suggest that the current schizophrenia
service configuration is not optimal. Cost savings and/or additional quality-adjusted life-years may be
gained by replacing current interventions with more cost-effective interventions.
JAMA Network Open. 2020;3(5):e205888. doi:10.1001/jamanetworkopen.2020.5888
Key Points
Question Which interventions are cost-
effective for the prevention and
treatment of schizophrenia?
Findings In this decision analytical
model using a simulated cohort of
200000 individuals, the following
interventions were found to be
cost-effective: practice as usual plus
cognitive behavioral therapy for
individuals at clinical high risk of
psychosis; a mix of hospital admission
and crisis resolution and home
treatment team for individuals with
acute psychosis; receipt of amisulpride,
risperidone, or olanzapine combined
with family intervention for individuals
with first-episode psychosis; and receipt
of clozapine for individuals with
treatment-resistant schizophrenia.
Meaning The results of this study
suggest that cost savings and/or
additional quality-adjusted life years
may be gained by replacing current
interventions with more cost-effective
interventions.
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Introduction
Economic models have increasingly been used to inform decision-making regarding health care, as
they provide an explicit way of synthesizing all available data to simulate the likely costs and
consequences of using alternative interventions under scenarios that cannot be directly observed in
the real world.1A 2020 systematic review found several limitations of existing economicmodels for
schizophrenia.2Most existingmodels (83%) focused on antipsychotic medications, while there was a
lack of models for nonpharmacologic interventions, such as cognitive behavioral therapy (CBT),
family intervention, and crisis resolution and home treatment team (CRHT). Second, no antipsychotic
medicationwas shown to be clearly cost-effective comparedwith the others because of inconsistent
or even contradictory conclusions reported by different studies. Third, the quality of existingmodels
was considered low. This systematic review highlighted issues relating to inconsistent assumptions
and uses of evidence, which negatively affect the quality of existing economic studies in
schizophrenia. Greater consistency could be achieved through the development of generic models
that have been agreed on by key stakeholders. A whole-disease model (WDM) represents a type of
generic model that is unique in that it can be used to informmultiple resource allocation decisions
across the entire care pathway.
Whole-disease models are large-scale models that involve simulating whole disease and
treatment pathways, thereby allowing for the economic evaluation of options for the prevention,
early identification, diagnosis, treatment, and follow-up of a given disease using a single consistent
model.3 This type of system-level modeling approach has been successfully applied to a number of
disease areas, including cancer, metabolic diseases, and cardiovascular diseases.4 However, such an
approach has not been applied to anymental health disorders.4 The aim of this studywas to develop
a WDM for schizophrenia services and use it to assess the cost-effectiveness of a range of
interventions in the UK.
Methods
This study was reported according to the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) reporting guideline for reporting health economic evaluations.5 Per the Common
Rule, ethical approval and informed patient consent were not required given that this is a modeling
study with no direct patient contact or influence on patient care directly related to this work.
Themethods for developing the schizophrenia WDMweremainly informed by the
methodologic framework set out by Tappenden et al.3 To help with the development and validation
of the WDM, a group of 13 multidisciplinary stakeholders was convened though snowball sampling.
The background of the 13 stakeholders included health care professionals practicing in the National
Health Service (9 [69.2%]), academic researchers with expertise in mental health economic
evaluation (12 [92.3%]), commissioners of mental health services (5 [38.5%]), and service users
(2 [15.4%]).
Population
The target population for themodel was individuals referred to secondary care mental health
services in the UK because of psychotic symptoms, with a mean (SD) age of 23.5 (5.1) years and a sex
ratio of 1.5:1 (men to women).6Of those referred, 33.2%were not at risk of psychosis, 34.9%were
at clinical high risk of psychosis (CHR-P), and 31.9% were individuals with psychosis.6 Those not at
risk of psychosis were included because they also use resources associated with schizophrenia
services (eg, specialist assessments).
Decision Problems
The decision problems to be addressed by theWDMwere identified from the scope of the
schizophrenia clinical guidelines developed by the National Institute for Health and Care Excellence
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(NICE).7,8 A total of 5 topics were identified (Table 1), which spanmost of the breadth of the
schizophrenia pathway, ranging from the use of CBT for individuals at CHR-P to antipsychotic
medication for individuals with treatment-resistant schizophrenia (TRS).
Outcomes and Cost Perspective
In accordance with the NICE Reference Case for economic evaluations,1 outcomes were valued in
terms of quality-adjusted life-years (QALYs), which are the product of health-related quality of life
and quantity of life lived (ie, survival). Costs included those relevant to the National Health Service
and Personal Social Services. Costs were reported in 2016 to 2017 UK pounds. Both costs and QALYs
were discounted at an annual rate of 3.5%.1
Statistical Analysis
Model Design and Implementation
For each intervention under assessment, the consequences of treatment were grouped into the
following 4 categories: clinical benefits (eg, preventing relapse), clinical harms (eg, adverse effects),
costs (eg, cost of providing the intervention and treating its adverse effects), and cost savings (eg,
reduced cost of treating relapse). Not all consequences of interventions were included; common
reasons for exclusion were that the treatment was not expected to affect patient outcomes and
there was a lack of evidence. For example, clinical harms were only modeled for antipsychotic
medications, not for psychosocial interventions because of a lack of adverse event data for
nonpharmacologic interventions. The key consequences of all interventions included in the
schizophrenia WDM are summarized in eAppendix 1 in the Supplement.
AWDMwith a lifetime horizon was implemented using discrete event simulation in SIMUL8
2019 software (Simul8 Corp). Discrete event simulation is an individual-level modeling approach in
which the clinical course of individual patients through the system is determined according to their
characteristics, previous events, and chance. The probability of events may be based on patient
history (eg, number of previous relapses) within themodel and demographic characteristics (eg, age
and sex). The implementedWDM covers 16 components (Figure), grouped into the following 4
modules: module A, initial assessment pathway; module B, CHR pathway; module C, psychosis
pathway; andmodule D, out-of-scope and death pathway. The overall model logic is described in
detail in eAppendix 2 in the Supplement. A list of key assumptions and simplifications of themodel is
presented in eAppendix 3 in the Supplement.
Under the traditional piecewise framework for economic evaluation, the assessment of each
decision problem listed in Table 1 would only involve running 1 part of the entire WDM (eg,
assessment of topic 1 would only involve running the CHR pathway). However, because the
underlying rationale of using aWDM approach is that all interventions are interrelated (ie, changes
made to 1 interventionmight affect the others), the entireWDMwas run repeatedly for each decision
problems listed in Table 1.
Input Data
In general, health economic models require 4 types of evidence, as follows: clinical evidence
(baseline event risks, treatment effects and adverse events); health-related quality of life estimates
(preference-based utility values); health care resource use; and costs. Model parameters were
informed by numerous evidence sources, including systematic reviews and meta-analyses, clinical
trials, clinical audits, observational studies, resource use surveys, costing studies, health valuation
studies, and expert opinion. Evidencewasmainly obtained from themeta-analyses conducted by the
NICE schizophrenia Guideline Development Groups,7,8 supplemented with new evidence identified
from rapid reviews of the literature conducted by the authors. A lack of evidence was identified for
many parameters, including the long-term clinical effectiveness and adverse effects of interventions
(eg, CBT, family intervention, and antipsychotic medications) and up-to-date costs of managing
patients with schizophrenia in remission. When no relevant data were identified, expert opinion was
Table 1. Decision Problems Addressed Using
the SchizophreniaWhole-DiseaseModel
Topic
Interventions and
comparators
Interventions for
patients at CHR-P
Practice as usual
Practice as usual plus 16
sessions of CBT
Interventions for
individuals with
acute psychosis
Hospital admission alone
Mix of hospital admission
and CRHT
First-line oral
antipsychotic
medication for FEP
Amisulpride
Aripiprazole
Haloperidol
Olanzapine
Placebo
Quetiapine
Risperidone
Family intervention
for FEP
Antipsychotic medication
alone
Family intervention alone
Antipsychotic medication
plus 20 sessions of family
intervention
First-line oral
antipsychotic
medication for TRS
Clozapine
Haloperidol
Olanzapine
Quetiapine
Risperidone
Abbreviations: CHR-P, clinical high risk of
psychosis; CRHT, crisis resolution and home
treatment team; CBT, cognitive behavioral
therapy; FEP, first-episode psychosis; TRS,
treatment-resistant schizophrenia.
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used to inform the requiredmodel parameters, with alternative plausible values tested in sensitivity
analyses. A summary of the keymodel parameters is reported in Table 2; a complete list of all model
parameters, including data sources, is reported in eAppendix 4 in the Supplement.
Model Checking
Extensive model verification and validation activities were undertaken, including white-box tests
(scrutinizing the programming code) and black-box tests (testing the behavior of themodel),9
checking results with stakeholders and comparing results with published literature. The details of
white-box and black-box tests conducted are reported in eAppendix 5 in the Supplement. The overall
model behavior was checked by 1 of us (P.T.). In addition, 7members of a service user advisory group
affiliated with theMaudsley Biomedical Research Centre, London, commented on themodel
structure and key assumptions.
Model EvaluationMethods
In accordance with the lower end of the cost-effectiveness threshold range used by NICE,
interventions with an incremental cost-effectiveness ratio lower than £20000 ($25 552) per QALY
were considered cost-effective.1 The incremental cost-effectiveness ratio was defined as the
difference in the expected cost of 2 interventions, divided by the difference in the expected effects
of the 2 interventions.
Extensive sensitivity analyses were undertaken to test the robustness of the results of the base
case analyses to different sets of assumptions and using different input data, including 1-way and
multiway sensitivity analysis to assess the consequences of uncertainty regarding the value of a
single or multiple parameter(s); structural sensitivity analysis to assess the consequences of
uncertainty regarding the structural assumptions of themodel (eg, whether CBT can prevent
psychosis or just delay the transition to psychosis); and probabilistic sensitivity analyses that examine
the consequences of joint uncertainty of multiple parameters simultaneously.
Figure. Model Structure
5. CHR on CBT
8. CHR recover
9. CHR convert
4. CHR wait for
CBT
10. Manage
acute psychosis
12. Nonacute
psychosis on AP
11. FEP wait for
treatment
15. Diagnosis
13. Psychosis
on FI
14. Psychosis
stop treatment
6. CHR under
monitoring
7. CHR not under
monitoring
1. Model entry
2. Assessment
3. Out of scope
16. Death
Receive
CBT
CHR FEP
Not at risk
Acute FEP
Stable FEP; do not receive
treatment
Stable FEP
receive
treatment
Receive
 monitoring only
Do not receive CBT
or monitoring
Accept AP
Accept FI only
Die Die
Module D: out of
scope and death
pathway
Module A:
Specialist 
assessment
pathway
Module B: CHR pathway Module C: Psychosis
pathway
Abbreviations: AP, antipsychotic medication; CBT, cognitive behavioral therapy; CHR, clinical high risk of psychosis; FEP, first-episode psychosis; and FI, family intervention.
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Table 2. Summary of Key Parameters Used in the SchizophreniaWhole-DiseaseModela
Parameter Baseline value Distribution
Epidemiologic data, %
Age, mean, y 23.52 Normal (SE, 2.85)
Men 60.40 Beta (α = 665.61; β = 436.39)
Starting disease status
Not at risk of psychosis 33.21 Dirichlet (n = 276, N = 831)
At CHR-P 34.90 Dirichlet (n = 290; N = 831)
FEP 31.89 Dirichlet (n = 265; N = 831)
Service provision data, %
CBT
Provision 41.01 Beta (α = 1011; β = 1454)
Take up 51.00 Beta (α = 510; β = 490)
Family intervention
Provision 30.98 Beta (α = 589; β = 1312)
Take up 38.49 Beta (α = 224; β = 358)
Antipsychotic
Provision 100.00 Assumed fixed
Take up for patients with FEP 97.38 Beta (α = 484; β = 13)
Delay in initiation of clozapine, y 3.98 Gamma (α = 137.25; β = 0.023)
Clinical effectiveness data: nonpharmacologic
interventions, RR
Transition to psychosis for CBT vs practice as usual 0.41 Log normal (ln[SE], 0.29)
Relapse for family intervention vs standard care
or other control
0.63 Log normal (ln[SE], 0.16)
Clinical effectiveness data: antipsychotic medication
for individuals with FEP, OR
Annual probability of all-cause discontinuation
for patients on placebo
0.82 Beta (α = 4949.54; β = 1079.87)
Amisulpride vs placebo 0.18 Log normal (ln[SE], 0.49)
Aripiprazole vs placebo 0.24 Log normal (ln[SE], 0.51)
Haloperidol vs placebo 0.21 Log normal (ln[SE], 0.34)
Olanzapine vs placebo 0.11 Log normal (ln[SE], 0.31)
Quetiapine vs placebo 0.21 Log normal (ln[SE], 0.32)
Risperidone vs placebo 0.15 Log normal (ln[SE], 0.40)
Haloperidol LAI vs placebo 0.15 Log normal (ln[SE], 0.45)
Paliperidone LAI vs placebo 0.19 Log normal (ln[SE], 0.53)
Clinical effectiveness data: antipsychotics for individuals
with TRS, OR
Annual probability of discontinuing clozapine because
of inefficacy
0.02 Beta (α = 4.98; β = 310.02)
Haloperidol vs clozapine 5.56 Log normal (ln[SE], 0.35)
Olanzapine vs clozapine 1.37 Log normal (ln[SE], 0.34)
Quetiapine vs clozapine 4.35 Log normal (ln[SE], 0.69)
Risperidone vs clozapine 2.27 Log normal (ln[SE], 0.40)
Health-related quality of life data
Individuals
At CHR-P 0.71 Beta (α = 100.22; β = 40.78)
With psychosis in remission 0.80 Normal (SE, 0.04)
With psychosis in relapse 0.67 Normal (SE, 0.06)
Disutility
Weight gain 0.03 Normal (SE, 0.01)
EPS 0.07 Normal (SE, 0.01)
Diabetes 0.09 Normal (SE, 0.05)
(continued)
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Following published guidance,10 a cohort of 200000 patients was adopted for deterministic
analyses and 1000 sampleswere used for probabilistic sensitivity analysis. The stability of results was
tested to different numbers of patients and probabilistic sensitivity analysis runs. No prespecified
level of statistical significance was set.
Results
The base case and probabilistic sensitivity analysis results are presented in Table 3 and summarized
in this section. The simulated cohort had a mean (SD) age of 23.5 (5.1) years, with 120800 (60.4%)
men, 66 400 (33.2%) not at risk of psychosis, 69 800 (34.9%) at CHR-P, and 63 800 (31.9%) with
psychosis.
Interventions for Patients at CHR-P
The base case analysis suggests that practice as usual plus CBT dominates practice as usual alone.
The cost savings of CBT are substantial (£1243 [$1588] per person), likely because the evidence used
to inform theWDM suggests that CBT can delay the transition from CHR-P to psychosis, and the
Table 2. Summary of Key Parameters Used in the SchizophreniaWhole-DiseaseModela (continued)
Parameter Baseline value Distribution
Cost data, £b
CBT
Cost per session 97.00 Gamma (α = 44.44; β = 2.18)
Sessions, No. 16 Assumed fixed
Family intervention
Cost per session 112.00 Gamma (α = 44.44; β = 2.52)
Sessions, No. 20 Assumed fixed
Oral antipsychotic, per d
Amisulpride 0.47 Gamma (α = 22.68; β = 0.02)
Aripiprazole 4.08 Gamma (α = 23.80; β = 0.17)
Haloperidol 0.37 Gamma (α = 30.86; β = 0.01)
Olanzapine 0.13 Gamma (α = 13.72; β = 0.01)
Quetiapine 1.24 Gamma (α = 6.25; β = 0.20)
Risperidone 0.36 Gamma (α = 5.41; β = 0.07)
Clozapine 1.56 Gamma (α = 156.25; β = 0.01)
LAI antipsychotic
Haloperidol, 28 d 6.56 Gamma (α = 13.72; β = 0.48)
Paliperidone, 30 d 334.45 Gamma (α = 82.64; β = 4.05)
Attendance at clozapine clinic 16.40 Gamma (α = 44.44; β = 0.37)
Managing patients with nonrelapsed schizophrenia, per y 14 983.45 Gamma (α = 2.04; β = 7341.89)
Assessing an acute episode of psychosis 507.00 Gamma (α = 348.55; β = 1.45)
CRHT team, per contact 197.45 Gamma (α = 44.44; β = 4.44)
Contacts with CRHT team, mean, No. 16.3 Gamma (α = 78.32; β = 0.21)
Hospital bed-day 379.00 Gamma (α = 44.44; β = 8.52)
Bed-days during 1 relapse, mean, No. 138.90 Weibull (α = 0.65; β = 0.61)
Cost of adverse events
Weight gain
Year 1 97.20 Gamma (α = 44.44; β = 2.19)
Year 2 onwards 309.68 Gamma (α = 3.77; β = 6755.56)
Acute EPS, per episode 51.95 Gamma (α = 44.44; β = 1.17)
Diabetes, per y 1336.31 Gamma (α = 124 044.44; β = 0.01)
Neutropenia, per episode 469.48 Gamma (α = 92 802.96; β = 0.01)
Abbreviations: CBT, cognitive behavioral therapy;
CHR-P, clinical high risk of psychosis; CRHT, crisis
resolution and home treatment team; EPS,
extrapyramidal symptoms; FEP, first-episode
psychosis; LAI, long-acting injectable; ln, natural log;
OR, odds ratio; RR, relative risk; TRS, treatment-
resistant schizophrenia.
a A complete list of all parameters used in the model
and their data sources are reported in eAppendix 3 in
the Supplement.
b To convert to US dollars, multiply by 1.2776.
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treatment cost for individuals with psychosis or schizophrenia ismuch higher than the treatment cost
for individuals at CHR-P. On the other hand, the QALY gains of CBT are marginal (5.19 × 10−5 per
person), likely because evidence used in theWDM suggests that the utility for individuals at CHR-P is
similar to individuals with psychosis. Assuming a willingness-to-pay (WTP) threshold of £20000
($25 552) per QALY gained, the probability that practice as usual plus CBT is cost-effective compared
to practice as usual alone was estimated to be 0.96.
Interventions for IndividualsWith Acute Psychosis
The base case analysis suggests that a mix of CRHT and hospital admission produces the same QALY
gains and additional cost savings (£3655 [$4670] per person) than hospital admission alone. This is
because the evidence used to inform the WDM suggests equivalent effectiveness between hospital
admission and CRHT,11 and the cost of hospital admission is much higher than the cost of CRHT
services. Assuming aWTP threshold of £20000 ($25 552) per QALY gained, the probability that a
mix of CRHT and hospital admission is cost-effective compared with hospital admission alone was
estimated to be 0.99.
Table 3. Deterministic and Probabilistic Results of Cost-effectiveness Analysis
Intervention
Deterministic results PSA results, per QALYa
Discounted mean Incremental
ICER WTP, £20 000b WTP, £30 000bCost per person, £b QALYs per person Cost, £b QALY
Interventions for patients at CHR-P
PAU plus CBT 167 452 19.1904 −1243 0.0000 Dominating 0.95 0.95
PAU alone 168 695 19.1904 NA NA Dominated 0.05 0.05
Interventions for individuals with
acute psychosis
Mix of hospital admission
and CRHT
168 078 19.1904 −3655 0.000 Dominating 1.00 1.00
Hospital admission alone 171 733 19.1904 NA NA Dominated 0.00 0.00
First-line oral antipsychotic
medication for FEP
Quetiapine 168 539 19.2005 1670 0.0071 235 211 0.06 0.06
Haloperidol 168 538 19.1981 NA NA Extendedly dominated 0.06 0.06
Aripiprazole 171 340 19.1977 NA NA Dominated 0.01 0.02
Risperidone 166 869 19.1934 1056 0.0112 94 286 0.30 0.30
Placebo 174 128 19.1931 NA NA Dominated 0.00 0.00
Amisulpride 165 813 19.1822 NA NA NA 0.39 0.39
Olanzapine 167 455 19.1794 NA NA Dominated 0.17 0.17
Family intervention for FEP
Antipsychotic medication plus
family intervention
167 905 19.2033 NA NA Dominating 0.58 0.62
Family intervention alone 175 065 19.1987 NA NA Dominated 0.09 0.10
Antipsychotic medication alone 168 261 19.1849 NA NA Dominated 0.33 0.28
First-line oral antipsychotic
medication for TRS
Clozapine 162 215 19.1977 NA NA Dominating 0.81 0.81
Olanzapine 165 444 19.1925 NA NA Dominated 0.16 0.16
Risperidone 169 324 19.1889 NA NA Dominated 0.03 0.03
Haloperidol 170 008 19.1883 NA NA Dominated 0.00 0.01
Quetiapine 172 043 19.1867 NA NA Dominated 0.00 0.00
Abbreviations: CBT, cognitive behavioral therapy; CHR-P, clinical high risk of psychosis;
CRHT, crisis resolution and home treatment team; FEP, first-episode psychosis; ICER,
incremental cost-effectiveness ratio; NA, not applicable; PAU, practice as usual; PSA,
probabilistic sensitivity analysis; QALY, quality-adjusted life-year; TRS, treatment-
resistant schizophrenia; WTP, willingness to pay.
a Probability for the intervention to bemost cost-effective within each topic.
b To convert to US dollars, multiply by 1.2776.
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First-LineOral AntipsychoticMedication for IndividualsWith FEP
The base case analysis suggests that, of the 7 interventions assessed, amisulpride was themost cost-
effective option, followed by risperidone and olanzapine. This is because the evidence used to inform
theWDM suggests that these antipsychotic medications are associated with the lowest probability
of all-cause drug discontinuation. Assuming aWTP threshold of £20000 ($25 552) per QALY gained,
amisulpride is most likely to be cost-effective (0.39), followed by risperidone (0.30) and olanzapine
(0.17). The probability of any antipsychotic medication being the most cost-effective option was less
than 0.05.
Family Intervention for IndividualsWith FEP
The base case analysis suggests that antipsychotic medication plus family intervention dominates
both antipsychotic alone and family intervention alone. This is because the evidence used to inform
theWDM suggests that family intervention can prevent relapse of psychosis, and the cost of treating
relapse is much higher than the cost of family intervention. Assuming aWTP threshold of £20000
($25 552) per QALY gained, the probability that antipsychotic medication plus family intervention is
themost cost-effective option comparedwithmedication or family intervention alonewas estimated
to be 0.58.
First-LineOral AntipsychoticMedications for IndividualsWith TRS
The base case analysis suggests that clozapine dominates all other antipsychotic medications. This is
because the evidence used in theWDM suggests that, of the 5 antipsychotics assessed for individuals
with TRS, clozapine was associated with the lowest all-cause discontinuation rate (including
discontinuation due to inefficacy, intolerability, and nonadherence) and was less likely to cause acute
extrapyramidal symptoms. Assuming aWTP threshold of £20000 ($25 552) per QALY gained, the
probability that clozapine is the most cost-effective option compared with other medications was
estimated to be 0.81.
Summary of Base Case Results
Assuming aWTP pay threshold of £20000 ($25 552) per QALY, themost cost-effective
interventions were practice as usual plus 16 sessions of CBT for individuals with CHR-P. Amix of CRHT
and hospital admission wasmost cost-effective for individuals with acute psychosis; amisulpride,
risperidone, or olanzapine combined with 20 sessions of family intervention wasmost cost-effective
for individuals with FEP; and clozapine wasmost cost-effective for individuals with TRS.
Sensitivity Analyses
The results of the sensitivity analyses are summarized in eAppendix 6 in the Supplement. They
suggest that the conclusions for interventions for patients at CHR-P, for individuals with acute
psychosis, and for first-line oral antipsychotic medication for those with FEP and TRS were robust to
all types of sensitivity analyses conducted. The conclusion for family intervention for individuals with
FEP was robust to all types of sensitivity analyses except the following: changes in the choice of
first-line antipsychotic; effectiveness of family intervention in preventing relapse; and number of
family intervention sessions provided. Antipsychotic medication alone was themost cost-effective
intervention when amisulpride was used as the first-line antipsychotic medications for individuals
with FEP; when the relative risk of family intervention in preventing relapse was increased from0.63
to 0.83; or when a brief (ie, number of sessions and effectiveness halved) version of family
intervention was assumed.
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Discussion
Comparing ResultsWith Published Literature
Comparison of our results with published literature by individual topic is detailed in eAppendix 7 in
the Supplement and summarized in this section. Our findings regarding interventions for patients at
CHR-P and with acute psychosis and for first-line oral antipsychotic medication for individuals with
FEP and with TRS are consistent with published literature.12-19 For first-line oral antipsychotic
medication for individuals with FEP, both the schizophrenia WDM and themodel developed by the
NICE schizophrenia Guideline Development Group7 found that no antipsychotic medication can be
considered clearly more cost-effective than the other options. However, the schizophrenia WDM
found amisulpride to be themost cost-effective option, while the NICEmodel suggests amisulpride
was the least cost-effective option. This is likely because of differences in the input data used. The
systematic review conducted by the NICE schizophrenia Guideline Development Group in 20087
found amisulpride to be associated with the second highest probability of relapse (second only to
haloperidol), while the latest systematic reviews,20,21which included additional trials, showed
amisulpride to be associated with among the lowest probabilities of all-cause discontinuation and
relapse rate.
Implications for Clinical Practice
The results of our analyses suggest that adoption of the following interventions could result in cost
savings compared with the current service: practice as usual plus 16 sessions of CBT for individuals at
CHR-P; a mix of hospital admission and CRHT for individuals with acute psychosis; antipsychotic
medication (amisulpride, risperidone, or olanzapine) combined with 20 sessions of family
intervention for individuals with FEP; and clozapine for individuals with TRS. Adoption of clozapine
for individuals with TRS also resulted in additional QALYs. The results suggest that a brief family
intervention (ie, 10 sessions) would not be cost-effective for individuals with FEP.
Strengths and Limitations
There are 3 key strengths of this study. First, it fills the evidence gap by presenting the first model-
based economic analysis of the following interventions: CBT for individuals with CHR-P, CRHT for
individuals with acute psychosis, family intervention for individuals with FEP, and clozapine and other
atypical antipsychotics for individuals with TRS. There has been an increased interest in investment
in brief family intervention because of resource constraints.22However, our study showed that while
a 20-session family intervention was cost-effective for individuals with FEP, a 10-session family
intervention was not. This findingmight change the current practice of providing family
interventions. Second, this study provides an up-to-date assessment of antipsychotic medication for
individuals with FEP based on the results of the latest network meta-analyses20,21 andmodeled the
cost and health consequences of 5 adverse effects of antipsychotics, including extrapyramidal
symptoms, weight gain, glucose intolerance, diabetes, and neutropenia. Our analysis found
amisulpride to be among themost cost-effective antipsychotics because of its therapeutic
superiority in preventing relapse. Considering the current market share of amisulpride in the UK (ie,
1.39%),23 our findingsmay change the current clinical practice of prescribing antipsychotics. Third, all
results presentedwithin this studywere based on awell-documentedWDM,which is populatedwith
input data carefully selected from high-quality literature. Extensive validation activities were
undertaken to ensure the quality of the schizophrenia WDM. To our knowledge, this is the first WDM
developed for the economic evaluation of a mental health disorder.
This study also has limitations. There are 2major limitations of the schizophrenia WDM
developed within this study. First, owing to resource constraints, input data for theWDMwere
obtained from published systematic reviews reported in the NICE schizophrenia guidelines,7,8
supplemented with new evidence identified from rapid reviews, rather than by undertaking our own
de novo systematic reviews. As such, it is possible that newer high-quality evidence has not been
JAMANetworkOpen | Psychiatry Cost-effectiveness of Services for Schizophrenia Across the Entire Care Pathway in aWhole-Disease Model
JAMA Network Open. 2020;3(5):e205888. doi:10.1001/jamanetworkopen.2020.5888 (Reprinted) May 27, 2020 9/12
Downloaded From: https://jamanetwork.com/ on 06/16/2020
included in themodel. Second, as with any health economic model, the credibility of the
schizophrenia WDM and its results are largely dependent on the quantity and quality of the evidence
used to inform it. While searching for input data for the WDM, a lack of evidence was identified for
many parameters, such as long-term clinical effectiveness and adverse effects of interventions (eg,
CBT, family intervention, and antipsychotics) and up-to-date costs of managing patients with
schizophrenia in remission. Even when evidence was available, it often had certain limitations, such
as variation in criteria for relapse, relatively short follow-up periods, unclear masking, incomplete
outcome data, and selective reporting. However, the model was designed to be adapted and reused,
and thus, results can be updated as new or better-quality evidence is identified.
Conclusions
The results of this study suggested that the following interventions are likely to be cost-effective:
CBT for individuals at CHR-P; a mix of hospital admission and CRHT for individuals with acute
psychosis; amisulpride, risperidone, or olanzapine combined with family intervention for individuals
with FEP; and clozapine for individuals with TRS. Cost savings and additional quality-adjusted life-
years may be gained by replacing current interventions with more cost-effective interventions.
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